Transgene Receives FDA Fast Track Status for TG4010 for Treatment of Non-Small Cell Lung Cancer
Transgene announced that the U.S. food & Drug Administration (FDA) has granted Fast Track development designation to its immunotherapy product TG4010 (MVA-MUC1-IL2) for the first-line treatment of advanced non-small cell lung cancer (NSCLC) in combination with chemotherapy.
The FDA determined that TG4010 meets the criteria for the Fast Track designation, facilitating the development of TG4010 for the first-line treatment in combination with chemotherapy to improve survival in patients with advanced MUC1-positive NSCLC and normal levels of activated Natural Killer (NK) cells. The granting of Fast Track status follows the FDA’s earlier clearance to proceed to phase III trial based on positive clinical data from a controlled phase IIb trial of TG4010 in patients with advanced NSCLC.
The phase IIb trial was a randomized, open label and controlled study designed to assess the efficacy of TG4010 in combination with cisplatin and gemcitabine compared to the chemotherapy regimen alone. The trial completed the enrolment of 148 patients at the end of May 2007 in 27 centres located in France, Poland, Germany, and Hungary. The trial met its primary end point with a progression-free survival at 6 months of 45 % in the experimental arm.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Antisoma's phase III trial of AS1413 completes patient enrolment
EMBO recognizes 63 researchers for advances in life sciences
Sensitizing tumor response to cancer therapy
PANATecs GmbH Appoints Rainer Baule, Chairman of the Board of Fresenius Kabi AG, to the Advisory Board

Siegfried begins construction of new large-scale production plant in Minden (DE) - Total investment of up to CHF 100 million

Wyss Institute at Harvard University launches SPEAR Bio - Spear Bio is working towards commercializing its first assay, which accurately assesses levels of SARS-CoV-2-neutralizing antibodies in dried-blood spot samples

HIV infection: the brevity of the right moment
Study sheds light on treating cancer - Using light to target and kill cancer cells alternatively without surgery

First structural map of cystic fibrosis protein sheds light on how mutations cause disease
Scientists identify gene that predicts post-surgical survival from brain metastasis of breast cancer patients

Silver nanoparticles take spectroscopy to new dimension - A new way of organizing nanostructures has boosted Raman signals by a hundred thousand times to better identify and characterize different molecules
